Key-vax

The Her-vax results are very encouraging although I don't think the fact one patient moved to CR is necessarily something that should have been announced to ASX as the trial has been completed. Some patients I would expect have probably already died (I don't know if this is the case or not) however it has no bearing on the trial results - believe it or not.
don't get me wrong the vaccine is looking brilliant so I am very much looking forward to some interim data later this year from the phase 2 trial. This trial will provide definitive data on the efficacy of the vaccine.

What I also find highly exciting though is the potential of the PD-1 HER-2 Combo Vaccine. Carefully examine slides 16 & 17 - you can see from the data results from the mouse cancer models conducted that our combo vaccine very significantly performed better when compared to Keytruda and Optivo which had undertaken the very exact trial (at an earlier time point). it provides a very clear signal that this could blow the lid off with multiple Pharma's wanting in. I am feeling 2019 will be a watershed year for IMU.